GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Replimune Group Inc (NAS:REPL) » Definitions » Earnings Yield (Joel Greenblatt) %

Replimune Group (Replimune Group) Earnings Yield (Joel Greenblatt) % : -158.73% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Replimune Group Earnings Yield (Joel Greenblatt) %?

Replimune Group's Enterprise Value for the quarter that ended in Dec. 2023 was $126.96 Mil. Replimune Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-202.92 Mil. Replimune Group's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -158.73%.

The historical rank and industry rank for Replimune Group's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

REPL' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10000   Med: 0   Max: No Debt
Current: No Debt

During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Replimune Group was 10000.00%. The lowest was -10000.00%. And the median was 0.00%.

REPL's Earnings Yield (Joel Greenblatt) % is ranked worse than
99.78% of 1394 companies
in the Biotechnology industry
Industry Median: -15.455 vs REPL: No Debt

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Replimune Group's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Replimune Group Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Replimune Group's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replimune Group Earnings Yield (Joel Greenblatt) % Chart

Replimune Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial -8.89 -21.23 -7.96 -26.25 -35.46

Replimune Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.60 -35.46 -19.72 -33.44 -158.73

Competitive Comparison of Replimune Group's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Replimune Group's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Replimune Group's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Replimune Group's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Replimune Group's Earnings Yield (Joel Greenblatt) % falls into.



Replimune Group Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Replimune Groups Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-169.836/478.276458
=-35.51 %

Replimune Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-202.92 Mil.



Replimune Group  (NAS:REPL) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Replimune Group Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Replimune Group's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Replimune Group (Replimune Group) Business Description

Industry
Traded in Other Exchanges
Address
500 Unicorn Park Drive, Suite 303, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Executives
Christopher Sarchi officer: Chief Commercial Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Konstantinos Xynos officer: Chief Medical Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Emily Luisa Hill officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pamela Esposito officer: Chief Business Officer C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Sushil Patel officer: Chief Commercial Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Tanya Lewis director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Veleka Peeples-dyer director C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Andrew Schwendenman officer: Chief Accounting Officer C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Philip Astley-sparke director, 10 percent owner, officer: Executive Chairman C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Robert Coffin director, 10 percent owner, officer: President and C.E.O. C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Love Colin 10 percent owner, officer: Chief Operating Officer C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 10801
Jean M. Franchi officer: Chief Financial Officer C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Omega Fund Iv Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Christy J. Oliger director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Jason P Rhodes director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139